<unk> , sold under the brand name Inqovi, is a fixed-dose combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). It is a combination of<unk> , a nucleoside metabolic inhibitor, and<unk> , a cytidine deaminase inhibitor. The most common side effects of<unk>  include fatigue, constipation, hemorrhage, muscle pain (myalgia), mucositis (mouth sores), arthralgia (joint pain), nausea, dyspnea, diarrhea, rash, dizziness, fever with low white blood cell count (febrile neutropenia), edema, headache, cough, decreased appetite, upper respiratory tract infection, pneumonia, and transaminase increased. The combination can cause fetal harm.<unk>  was approved for medical use in the United States and in Canada in July 2020.
Decitabine/cedazuridine
Trifluridine/tipiracil
Zalcitabine
Trifluridine
Bortezomib/dexamethasone
Daunorubicin/cytarabine
Apricitabine
Lenalidomide